JP2016538248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538248A5 JP2016538248A5 JP2016521604A JP2016521604A JP2016538248A5 JP 2016538248 A5 JP2016538248 A5 JP 2016538248A5 JP 2016521604 A JP2016521604 A JP 2016521604A JP 2016521604 A JP2016521604 A JP 2016521604A JP 2016538248 A5 JP2016538248 A5 JP 2016538248A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890154P | 2013-10-11 | 2013-10-11 | |
| US61/890,154 | 2013-10-11 | ||
| US201461923103P | 2014-01-02 | 2014-01-02 | |
| US61/923,103 | 2014-01-02 | ||
| US201461955514P | 2014-03-19 | 2014-03-19 | |
| US61/955,514 | 2014-03-19 | ||
| US201462004620P | 2014-05-29 | 2014-05-29 | |
| US62/004,620 | 2014-05-29 | ||
| US201462025104P | 2014-07-16 | 2014-07-16 | |
| US62/025,104 | 2014-07-16 | ||
| EP14306221 | 2014-07-31 | ||
| EP14306221.4 | 2014-07-31 | ||
| US201462054571P | 2014-09-24 | 2014-09-24 | |
| US62/054,571 | 2014-09-24 | ||
| EP14306584 | 2014-10-09 | ||
| EP14306584.5 | 2014-10-09 | ||
| PCT/US2014/060109 WO2015054619A2 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019146940A Division JP6994484B2 (ja) | 2013-10-11 | 2019-08-09 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538248A JP2016538248A (ja) | 2016-12-08 |
| JP2016538248A5 true JP2016538248A5 (https=) | 2017-11-16 |
| JP6846931B2 JP6846931B2 (ja) | 2021-03-24 |
Family
ID=52813751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521604A Active JP6846931B2 (ja) | 2013-10-11 | 2014-10-10 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
| JP2019146940A Active JP6994484B2 (ja) | 2013-10-11 | 2019-08-09 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019146940A Active JP6994484B2 (ja) | 2013-10-11 | 2019-08-09 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150140002A1 (https=) |
| EP (2) | EP3055333B1 (https=) |
| JP (2) | JP6846931B2 (https=) |
| KR (3) | KR20160062166A (https=) |
| CN (3) | CN105814085A (https=) |
| AU (2) | AU2014331754B2 (https=) |
| CA (1) | CA2926942A1 (https=) |
| EA (1) | EA037526B1 (https=) |
| ES (1) | ES2914978T3 (https=) |
| IL (1) | IL244995B (https=) |
| MX (3) | MX373298B (https=) |
| PL (2) | PL3055333T4 (https=) |
| TW (1) | TWI669131B (https=) |
| WO (1) | WO2015054619A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| SG192117A1 (en) | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| CN118105480A (zh) | 2013-11-12 | 2024-05-31 | 赛诺菲生物技术公司 | 用于与pcsk9抑制剂一起使用的给药方案 |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| US20180140747A1 (en) * | 2015-04-15 | 2018-05-24 | ConcieValve LLC | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| KR20190049866A (ko) | 2016-09-20 | 2019-05-09 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-ｐｃｓｋ９ 항체 |
| JP7050807B2 (ja) | 2017-04-13 | 2022-04-08 | カディラ ヘルスケア リミティド | 新規ペプチドベースのｐｃｓｋ９ワクチン |
| EP3615694B1 (en) | 2017-04-25 | 2022-03-30 | The Brigham and Women's Hospital, Inc. | Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis |
| CN107090474A (zh) * | 2017-05-22 | 2017-08-25 | 山东大学 | 一种腹主动脉瘤疾病动物模型的制备方法 |
| CN109963877B (zh) * | 2017-06-14 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| TW201945401A (zh) * | 2018-03-06 | 2019-12-01 | 法商賽諾菲生物技術公司 | 降低心血管風險的方法 |
| IL279363B2 (en) | 2018-06-21 | 2025-12-01 | Merck Sharp & Dohme | Pcsk9 antagonist compounds |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| IL292973B2 (en) * | 2019-11-18 | 2026-03-01 | Ad Pharmaceuticals Co Ltd | Anti-PCSK9 antibody and its use |
| WO2021119321A1 (en) * | 2019-12-10 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
| EP4076492A4 (en) | 2019-12-20 | 2024-01-17 | Merck Sharp & Dohme LLC | PCSK9 ANTAGONIST COMPOUNDS |
| CN114277032A (zh) * | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | 一种低密度脂蛋白受体基因突变体及其应用 |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US8357371B2 (en) * | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| SG192117A1 (en) * | 2011-01-28 | 2013-08-30 | Sanofi Sa | Human antibodies to pcsk9 for use in methods of treating particular groups of subjects |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HUE069234T2 (hu) * | 2011-09-16 | 2025-02-28 | Regeneron Pharma | Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával |
| TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
-
2014
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active Ceased
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en not_active Ceased
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Ceased
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Ceased
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 MX MX2016004580A patent/MX373298B/es active IP Right Grant
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
-
2016
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
-
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
-
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538248A5 (https=) | ||
| JP2017528427A5 (https=) | ||
| JP2022177142A5 (https=) | ||
| JP2017506626A5 (https=) | ||
| US12606638B2 (en) | Dosing regimens for use with PCSK9 inhibitors | |
| JP2016538277A5 (https=) | ||
| JP2024147744A (ja) | 心血管リスクを低減させる方法 | |
| JP2019514907A5 (https=) | ||
| JP2016520616A5 (https=) | ||
| JP2017522316A5 (https=) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2016522211A5 (https=) | ||
| JP2015503588A5 (https=) | ||
| HRP20200545T1 (hr) | Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom | |
| Di Ciaula et al. | Therapeutic reflections in cholesterol homeostasis and gallstone disease: a review | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2016523847A5 (https=) | ||
| JP2017533191A5 (https=) | ||
| JP2015503590A5 (https=) | ||
| JP2022078306A (ja) | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 | |
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| RU2016129266A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP2019533715A5 (https=) |